$89.13 0.6 0.7%
Last Trade - 26/02/21
| Market Cap | ÂŁ3.74bn |
| Enterprise Value | ÂŁ3.60bn |
| Revenue | ÂŁ17.2k |
| Position in Universe | 1342nd / 6715 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.018 | 0.007 | 2.15 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines based on its base editing technology, to providing life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). It is advancing a broad, diversified portfolio of 12 base editing programs against distinct editing targets. Its programs are organized by delivery modality into three distinct pipelines: electroporation for delivery to blood cells and immune cells; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future; and adeno-associated viral vectors (AAV), for viral delivery to the eye and central nervous system (CNS).
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | January 25, 2017 |
| No. of Shareholders: | 85 |
| No. of Employees: | 118 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 58,418,198 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 26 Landsdowne St, CAMBRIDGE, 02139-4216, United States |
| Web | https://beamtx.com/ |
| Phone | +1 857 3278775 |
| Contact | () |
| Auditors | Deloitte & Touche LLP |
As of 26/02/21, shares in Beam Therapeutics Inc are trading at $89.13, giving the company a market capitalisation of ÂŁ3.74bn. This share price information is delayed by 15 minutes.
Shares in Beam Therapeutics Inc are currently trading at $89.13 and the price has moved by 0.289k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Beam Therapeutics Inc price has moved by 0.200k% over the past year.
There are no analysts currently covering Beam Therapeutics Inc.
Beam Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:
Beam Therapeutics Inc does not currently pay a dividend.
Beam Therapeutics Inc does not currently pay a dividend.
Beam Therapeutics Inc does not currently pay a dividend.
To buy shares in Beam Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Beam Therapeutics Inc are currently trading at $89.13, giving the company a market capitalisation of ÂŁ3.74bn.
Here are the trading details for Beam Therapeutics Inc:
Based on an overall assessment of its quality, value and momentum, Beam Therapeutics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Beam Therapeutics Inc are currently priced at $89.13. At that level they are trading at 7.15% discount to the analyst consensus target price of 0.00.
Analysts covering Beam Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.017 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beam Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 0.227k%. At the current price of $89.13, shares in Beam Therapeutics Inc are trading at 88.95% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Beam Therapeutics Inc.
Beam Therapeutics Inc's management team is headed by:
Here are the top five shareholders of Beam Therapeutics Inc based on the size of their shareholding:
